title: Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
abstract: BACKGROUND
  Description of the cutaneous side effects of erlotinib.
  
  
  METHODS
  Report with images of a single case.
  
  
  METHODS
  Case report and review of the literature.
  
  
  CONCLUSIONS
  Erlotinib is associated with significant cutaneous toxicity which should be recognised and managed appropriately.
authors.affiliation: Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland. pforde1980@hotmail.com
authors.forename: P
authors.initials: P
authors.lastname: Forde
authors.forename: C
authors.initials: C
authors.lastname: Murphy
authors.forename: C
authors.initials: C
authors.lastname: O'Sullivan
authors.forename: D
authors.initials: D
authors.lastname: Carney
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000505:Alopecia / Q000139:chemically induced*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors